To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients

计划入组 100 人 · 首次发布于 2020 年 7 月 13 日

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

计划入组 12 人 · 首次发布于 2016 年 7 月 1 日

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

计划入组 14 人 · 首次发布于 2016 年 1 月 13 日

Aprepitant(Aponvie, Cinvanti, Emend)

C₂₃H₂₁F₇N₄O₃ · Rx

Sar9, Met (O2)11-Substance P

C₆₄H₁₀₀N₁₈O₁₅S

substance P antagonists (Adelaide University)

SUBSTANCE PTY LTD

Australia

Arvinas Estrogen Receptor, Inc.

United States

NHI-1

United States

Hoth Therapeutics Receives US Patent for HT-ALZ, a Novel Alzheimer's Treatment

Heron Therapeutics Settles Patent Litigation with Mylan for CINVANTI and APONVIE

Eolas Therapeutics Assumes Full Development Rights to First-in-Class Orexin-1 Receptor Antagonist AZD4041 for Substance Use Disorders